

	<p>Genetic Testing Guidelines</p>	
<p>Guideline # 6181</p>	<p>Categories Clinical →Care Management CM, TCHP Guidelines, Utilization Management UM</p>	<p>This Guideline Applies To: Texas Children's Health Plan</p>
		<p>Document Owner Lisa Hollier</p>

GUIDELINE STATEMENT:

Texas Children's Health Plan (TCHP) performs authorization of all genetic testing requests.

PRIOR AUTHORIZATION GUIDELINES

1. Genetic testing conducted by out-of-network providers will be treated as out-of-network requests and will comply with the out-of-network authorization Guidelines.
2. Requests for Noninvasive Prenatal Testing will comply with TCHP Noninvasive Prenatal Testing Guidelines.
3. All requests for prior authorization for genetic testing are received via fax, phone or mail by the Utilization Management Department and processed during normal business hours.
4. The Utilization Management professional receiving the request evaluates the submitted information to determine if the documentation supports the genetic testing as an eligible service.
5. To request prior authorization for genetic testing, documentation supporting the medical necessity of the test requested must be provided.
6. TCHP will apply clinical criteria in the current Texas Medicaid Provider Manual (TMPPM) at the time of the request when applicable for the following:
 - 6.1. BRCA gene mutation analysis
 - 6.2. Genetic Testing for colorectal cancer
 - 6.3. Cytogenetic testing
 - 6.4. Pharmacogenetic Testing

6.5. A request for retroactive authorization must be submitted no later than seven calendar days beginning the day after the lab draw is performed per TMPPM

7. Whole genome sequencing (code 81415) requires preauthorization on a case-by-case basis.
8. Trio Whole exome sequencing (WES procedure code 81416) is not a benefit as Texas Children's Health Plan does not cover genetic testing involving non- Texas Children's Health Plan members even when it will provide genetic information for a TCHP member.
9. Utilization Management professionals will utilize the most recent available version of InterQual criteria for genetic testing to establish medical necessity when applicable.
10. In cases where the clinical reason for the genetic testing is not clearly stated in the Interqual criteria, TCHP considers the following as indications for medically necessary genetic testing:

10.1. Preconception or prenatal carrier screening recommended by the American College of Obstetricians and Gynecologists (ACOG)

10.1.2. A request for retroactive authorization must be submitted no later than seven calendar days beginning the day after the lab draw is performed

10.1.3 Preconception or prenatal carrier screening is a benefit once per lifetime of the member

10.1.4. Preconception or prenatal carrier screening for couples of Ashkenazi Jewish ancestry with a panel of genetic tests as recommended by the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG)

10.1.4.1. The panel should include:

- 10.4.1.1. Tay Sachs disease
- 10.4.1.2. Canavan disease
- 10.4.1.3. Cystic fibrosis
- 10.4.1.4. Familial dysautonomia
- 10.4.1.5. Bloom syndrome
- 10.4.1.6. Familial Hyperinsulinism,
- 10.4.1.7. Niemann-Pick disease
- 10.4.1.8. Usher Syndrome
- 10.4.1.9. Mucopolysaccharidosis IV
- 10.4.1.10 Fanconi anemia
- 10.4.1.11 Gaucher Disease
- 10.4.1.12 Glycogen Storage Disease type I
- 10.4.1.13 Joubert Syndrome
- 10.4.1.14 Maple Syrup Urine Disease

10.2. Genetic testing of the individual's genome for inherited diseases is considered **medically necessary** when the following criteria are met:

10.2.1. The individual for whom the test is requested:

1. Is asymptomatic but is judged to be at significant risk, as determined by the likelihood of future disease and burden of suffering, for a genetic disease (for example, based on family history); **or**
2. Is currently symptomatic with suspicion of a known genetic disease; **and**

10.2.2. All of the following criteria apply:

- 10.2.2.1. A specific mutation, or set of mutations, has been established in the scientific literature to be reliably associated with the disease; **and**
- 10.2.2.4. Results of the genetic test, whether affirmative or negative, will impact the clinical management (predictive, diagnostic, prognostic or therapeutic) of the Individual. For example, genetic test results will guide treatment decisions, surveillance recommendations or preventive strategies; **and**
- 10.2.2.5. The findings of the genetic test will likely result in an anticipated improvement in net health outcomes; that is, the expected health benefits of the interventions outweigh any harmful effects (medical or psychological) of the intervention; **and**
- 10.2.2.6. Testing is accompanied by genetic counseling.

10.3.. The individual is suspected of having one of the following diagnosis (this list is not all-inclusive):

- 10.3.1. Achondroplasia (FGFR3)
- 10.3.2. Albinism
- 10.3.3. Alpha-1 antitrypsin deficiency (SERPINA1)
- 10.3.4. Classical lissencephaly
- 10.3.5. Congenital adrenal hyperplasia/21 hydroxylase deficiency (CYP21A2)*
- 10.3.6. Congenital amegakaryocytic thrombocytopenia
- 10.3.7. Congenital central hypoventilation syndrome (PHOX2B)
- 10.3.8. Congenital muscular dystrophy
- 10.3.9. Type 1C (MDC1C) (FKRP (Fukutin related protein))
- 10.3.10. Crouzon syndrome (FGFR2, FGFR3)
- 10.3.11. Dentatorubral-pallidoluysian atrophy
- 10.3.12. Dysferlin myopathy
- 10.3.13. Ehlers-Danlos syndrome
- 10.3.14. Emery-Dreifuss muscular dystrophy (EDMD1, 2, and 3)
- 10.3.15. Familial Mediterranean fever (MEFV)
- 10.3.16. Facioscapulohumeral muscular dystrophy (FSHMD1A)
- 10.3.17. Friedreich's ataxia (FRDA (frataxin))
- 10.3.18. Gitelman's syndrome
- 10.3.19. Hemoglobin E thalassemia
- 10.3.20. Hemoglobin S and/or C
- 10.3.21. Hereditary amyloidosis (TTR variants)
- 10.3.22. Hereditary deafness (GJB2 (Connexin-26, Connexin-32))
- 10.3.23. Hereditary hemorrhagic telangiectasia (HHT)

- 10.3.24 Hereditary hemochromatosis (HFE) (see below)
- 10.3.25. Hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome (fumarate hydratase (FH) gene)
- 10.3.26. Hereditary neuropathy with liability to pressure palsies (HNPP)
- 10.3.27. Hereditary non-polyposis colorectal cancer (HNPCC) (MLH1, MSH2, MSH6, MSI) (see below)
- 10.3.28. Hereditary pancreatitis (PRSS1) (see below)
- 10.3.29. Hereditary paraganglioma (SDHD, SDHB)
- 10.3.30. Hypochondroplasia (FGFR3)
- 10.3.31. Jackson-Weiss syndrome (FGFR2) Kallmann syndrome (FGFR1)
- 10.3.32. Kennedy disease (SBMA)
- 10.3.33. Leber hereditary optic neuropathy (LHON)
- 10.3.34. Leigh Syndrome and NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa)
- 10.3.35. Limb girdle muscular dystrophy (LGMD1, LGMD2) (FKRP (Fukutin related protein))
- 10.3.36. Malignant hyperthermia (RYR1)
- 10.3.37. McArdle's disease
- 10.3.38. Medium chain acyl coA dehydrogenase deficiency (ACADM)
- 10.3.39. Medullary thyroid carcinoma
- 10.3.40. MELAS (mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes) (MTTL1, tRNA^{Leu})
- 10.3.41. Mucopolysaccharidoses type 1 (MPS-1)
- 10.3.42. Muenke syndrome (FGFR3)
- 10.3.43. Multiple endocrine neoplasia type 1
- 10.3.44. Muscle-Eye-Brain disease (POMGNT1)
- 10.3.45. MYH-associated polyposis (MYH) (see below)
- 10.3.46. Myoclonic epilepsy (MERRF) (MTTK (tRNA^{Lys}))
- 10.3.47. Myotonic dystrophy (DMPK, ZNF-9)
- 10.3.48. Nephrotic syndrome, congenital (NPHS1, NPHS2)
- 10.3.49. Neurofibromatosis type 1 (NF1, neurofibromin)
- 10.3.50. Neurofibromatosis type 2 (Merlin)
- 10.3.51. Neutropenia, congenital cyclic
- 10.3.52. Phenylketonuria (PAH)
- 10.3.53. Pfeiffer syndrome (FGFR1)
- 10.3.54. Prader-Willi-Angelman syndrome (SNRPN, GABRA5, NIPA1, UBE3A, ANCR, GABRA)
- 10.3.55. Primary dystonia (TOR1A (DYT1))
- 10.3.56. Prothrombin (F2 (Factor II, 20210G> A mutation))
- 10.3.57. Pyruvate kinase deficiency (PKD)
- 10.3.58. Retinoblastoma (Rh)
- 10.3.59. Saethre-Chotzen syndrome (TWIST, FGFR2)
- 10.3.60. Smith-Lemli-Opitz syndrome
- 10.3.61. Spinocerebellar ataxia (SCA types 1, 2, 3 (MJD), 6 (CACNA1A), 7, 8, 10, 17 and DRPLA)
- 10.3.62. Thanatophoric dysplasia (FGFR3)
- 10.3.63. Von Gierke disease (G6PC, Glycogen storage disease, Type 1a)

10.3.64. Walker-Warburg syndrome (POMGNT1)

10.3.65. 22q11 deletion syndromes (DCGR (CATCH-22))

10.3. In the following condition specific situations:

10.3.1. Suspicion of Catecholaminergic polymorphic ventricular tachycardia (CPVT) in:

10.3.1.1. Children or young adults (less than 40 years of age) with a 1st degree relative with a clinical diagnosis of CPVT, or a 1st or 2nd degree relative with a defined CPVT mutation; or

10.3.1.2. Persons who display exercise- or emotion-induced PVT or ventricular fibrillation, occurring in a structurally normal heart.

10.3.2. Factor V Leiden genetic testing for members with any of the following indications:

10.3.2.1. Age less than 50, any venous thrombosis; or

10.3.2.2. Myocardial infarction in female smokers under age of 50; or

10.3.2.3. Recurrent venous thrombosis; or

10.3.2.4. Relatives of individuals with venous thrombosis under age of 50; or

10.3.2.5. Venous thrombosis and a strong family history of thrombotic disease; or

10.3.2.6. Venous thrombosis in pregnant women or women taking oral contraceptives; or

10.3.2.7. Venous thrombosis in unusual sites (such as hepatic, mesenteric, and cerebral veins).

10.3.3. Genetic testing in **asymptomatic** blood relatives of persons with genetically confirmed Thoracic Aortic Aneurysms (TAAD).

10.3.4. Genetic testing for COL1A1 and COL1A2 gene sequencing in the management of osteogenesis imperfecta types I to IV for the following indications:

10.3.4.1. Genetic testing for sequence variants in COL1A1/2 to confirm the presence of mosaicism in the asymptomatic parent of a child with OI caused by sequence variants in COL1A1/2 for reproductive decision making purposes; or

10.3.4.2. Preimplantation genetic diagnosis or prenatal diagnosis for sequence variants in COL1A1/2 in couples in which 1 or both members have OI caused by sequence variants in COL1A1/2.

10.3.5. Cadherin-1 (e-cadherin, CDH1) for hereditary diffuse gastric cancer (HDGC) necessary for persons who meet the following criteria:

10.3.5.1. Individuals with HDGC for the purpose of identifying a CDH1 gene sequence variant that may be used to screen at-risk first- and second-degree relatives; or

10.3.5.2. Presymptomatic testing of first- and second-degree at-risk relatives for a known familial variant in the CDH1 gene.

10.3.6. Genetic testing for maturity-onset diabetes of the young (MODY) in persons with hyperglycemia or non-insulin-dependent diabetes who have any of the following:

10.3.6.1. A family history of abnormal glucose metabolism in at least 2 consecutive generations

10.3.6.2. ≥ 1 family members diagnosed before age 25.

10.3.7. TP53 gene testing in individuals with a suspected or known clinical diagnosis of Li-Fraumeni syndrome (LFS) or Li-Fraumeni-Like syndrome, or a known family history of a TP53 mutation.

10.4 For the members with a diagnosis of Autism the following genetic testing may be considered medically necessary if documentation supporting the medical necessity of the test requested is submitted as recommended by the American College of Medical Genetics (ACMG):

10.4.1 Chromosomal Microarray (CMA)

10.4.2 Fragile X syndrome

10.4.3 Methyl-CPG-binding protein 2 (MECP2) spectrum disorders

10.4.4 Phosphatase and tensin homolog (PTEN) related conditions

10.4.5 Karyotype

10.5. Clinical risk verified by TCHP Medical Director/Physician Reviewer

11. In the absence of specific information regarding advances in the knowledge of mutation characteristics for a particular disorder, the current literature indicates that genetic tests for inherited disease need only be conducted once per lifetime of the member.

12. Genetic testing of Texas Children's Health Plan members is excluded from coverage under Texas Children's Health Plan's benefit plans if the testing is performed primarily for the medical management of other family members who are not covered under a Texas Children's Health Plan benefit plan. In these circumstances, the insurance carrier for the family members who are not covered by Texas Children's Health Plan should be contacted regarding coverage of genetic testing. Texas Children's Health Plan does not cover genetic testing for heritable disorders in non-Texas Children's Health Plan members

13. Requests that do not meet the criteria established by this procedure will be referred to a TCHP Medical Director/Physician Reviewer for review and the Denial Policy will be followed.

14. Preauthorization is based on medical necessity and not a guarantee of benefits or eligibility. Even if preauthorization is approved for treatment or a particular service, that authorization applies only to the medical necessity of treatment or service. All services are subject to benefit limitations and exclusions. Providers are subject to State and Federal Regulatory compliance and failure to comply may result in retrospective audit and potential financial recoupment.

REFERENCES:

Peer Reviewed Publications:

- Abdeen H, Heggarty S, Hawkins SA, et al. Mapping candidate non-MHC susceptibility regions to multiple sclerosis. *Genes Immun*. 2006; 7(6):494-502.
- Aragon-Martin JA, Ritch R, Liebmann J, et al. Evaluation of LOXL1 gene polymorphisms in exfoliation syndrome and exfoliation glaucoma. *Mol Vis*. 2008; 17(14):533-541.
- Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. *Nat Rev Genet*. 2011; 12(11):745-755.
- Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. *Genet Med*. 2012; 14(4):393-398.
- Bilguvar K, Ozturk AK, Louvi A, et al. Whole-exome sequencing identifies recessive WDR62 mutations in severe brain malformations. *Nature*. 2010; 467(7312):207-210.
- Cauchi S, El Achhab Y, Choquet H, et al. TCF7L2 is reproducibly associated with type 2 diabetes in various ethnic groups: a global meta-analysis. *J Mol Med*. 2007; 85(7):777-782.
- Cauchi S, Meyre D, Choquet H, et al.; DESIR Study Group. TCF7L2 variation predicts hyperglycemia incidence in a French general population: the data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. *Diabetes*. 2006; 55(11):3189-3192.
- Chakrabarti S, Rao KN, Kaur I, et al. The LOXL1 gene variations are not associated with primary open-angle and primary angle-closure glaucomas. *Invest Ophthalmol Vis Sci*. 2008; 49(6):2343-2347.
- Challa P, Schmidt S, Liu Y, et al. Analysis of LOXL1 polymorphisms in a United States population with pseudoexfoliation glaucoma. *Mol Vis*. 2008; 14:146-149.
- Choi M, Scholl UI, Ji W, et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. *Proc Natl Acad Sci U S A*. 2009; 106(45):19096-19101.
- Clayton-Smith J, O'Sullivan J, Daly S, Bhaskar S, et al. Whole-exome-sequencing identifies mutations in histone acetyltransferase gene KAT6B in individuals with the Say-Barber-Biesecker variant of Ohdo syndrome. *Am J Hum Genet*. 2011; 89(5):675-681.
- De Silva NM, Steele A, Shields B, et al. The transcription factor 7-like 2 (TCF7L2) gene is associated with Type 2 diabetes in UK community-based cases, but the risk allele frequency is reduced compared with UK cases selected for genetic studies. *Diabet Med*. 2007; 24(10):1067-1072.
- Elashoff MR, Nuttall R, Beineke P, et al. Identification of factors contributing to variability in a blood-based gene expression test. *PLoS One*. 2012; 7(7):e40068.
- Elashoff MR, Wingrove JA, Beineke P, et al. Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients. *BMC Med Genomics*. 2011; 4:26.
- Elbein SC. Evaluation of polymorphisms known to contribute to risk for diabetes in African and African-American populations. *Curr Opin Clin Nutr Metab Care*. 2007; 10(4):415-419.
- Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. *BMJ*. 2001; 322(7293):1052-1056.
- Fan BJ, Pasquale L, Grosskreutz CL, et al. DNA sequence variants in the LOXL1 gene are associated with pseudoexfoliation glaucoma in a U.S. clinic-based population with broad ethnic diversity. *BMC Med Genet*. 2008; 6(9):5.
- Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med*. 2006; 355(3):241-250.
- Florez JC. The new type 2 diabetes gene TCF7L2. *Curr Opin Clin Nutr Metab Care*. 2007; 10(4):391-396.

- Frayling TM. A new era in finding Type 2 diabetes genes-the unusual suspects. *Diabet Med*. 2007; 24(7):696-701.
- Grarup N, Andersen G. Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism. *Curr Opin Clin Nutr Metab Care*. 2007; 10(4):420-426.
- Gudbjartsson DF, Arnar DO, Helgadóttir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. *Nature*. 2007; 448(7151):353-357.
- Herman L, Froelich J, Kanelos D, et al. Utility of a genomic-based, personalized medicine test in patients presenting with symptoms suggesting coronary artery disease. *J Am Board Fam Med*. 2014; 27(2):258-267.
- Lee H, Deignan JL, Dorrani N, et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. *JAMA*. 2014; 312(18):1880-1887.
- Lee RK. The molecular pathophysiology of pseudoexfoliation glaucoma. *Curr Opin Ophthalmol*. 2008; 19(2):95-101.
- Lettre G, Rioux JD. Autoimmune diseases: insights from genome-wide association studies. *Hum Mol Genet*. 2008; 17(R2):R116-121.
- Liu Y, Schmidt S, Qin X, et al. Lack of association between LOXL1 variants and primary open-angle glaucoma in three different populations. *Invest Ophthalmol Vis Sci*. 2008. 49(8):3465-3468.
- Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. *N Engl J Med*. 2008; 359(21):2220-2232.
- Lyssenko V, Lupi R, Marchetti P, et al. Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. *J Clin Invest*. 2007; 117(8):2155-2163.
- McPherson JA, Davis K, et al. The clinical utility of gene expression testing on the diagnostic evaluation of patients presenting to the cardiologist with symptoms of suspected obstructive coronary artery disease: results from the IMPACT (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial. *Crit Path Cardiol*. 2013; 12(2):37-42.
- McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. *Science*. 2007; 316(5830):1488-1491.
- Meigs JB, Shrader P, Sullivan LM, et al. Genotype score in addition to common risk factors for prediction of type 2 diabetes. *N Engl J Med*. 2008; 359(21):2208-2219.
- Miyake K, Horikawa Y, Hara K, et al. Association of TCF7L2 polymorphisms with susceptibility to type 2 diabetes in 4,087 Japanese subjects. *J Hum Genet*. 2008; 53(2):174-180.
- Mossbock G, Renner W, Faschinger C, et al. Lysyl oxidase-like protein 1 (LOXL1) gene polymorphisms and exfoliation glaucoma in a Central European population. *Mol Vis*. 2008; 9(14):857-861.
- Owen KR, McCarthy MI. Genetics of type 2 diabetes. *Curr Opin Genet Dev*. 2007; 17(3):239-244.
- Ozaki M, Lee KY, Vithana EN, et al. Association of LOXL1 gene polymorphisms with pseudoexfoliation in the Japanese. *Invest Ophthalmol Vis Sci*. 2008; 49(9):3976-3980.
- Palmer ND, Lehtinen AB, Langefeld CD, et al. Association of TCF7L2 gene polymorphisms with reduced acute insulin response in Hispanic Americans. *J Clin Endocrinol Metab*. 2008; 93(1):304309.
- Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. *JAMA*. 2010; 303(7):648-656.

- Pasutto F, Krumbiegel M, Mardin CY, et al. Association of LOXL1 common sequence variants in German and Italian patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. *Invest Ophthalmol Vis Sci*. 2008; 49(4):1459-1463.
- Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. *Ann Intern Med*. 2009; 150(2):65-72.
- Ramprasad VL, George R, Soumitra N, et al. Association of non-synonymous single nucleotide polymorphisms in the LOXL1 gene with pseudoexfoliation syndrome in India. *Mol Vis*. 2008; 9(14):318-322.
- Ropers HH. New perspectives for the elucidation of genetic disorders. *Am J Hum Genet*. 2007; 81(2):199-207.
- Rosenberg S, Elashoff MR, Beineke P, et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. *Ann Intern Med*. 2010; 153(7):425-434.
- Saito H, Osaka H, Sasaki M, et al. Mutations in POLR3A and POLR3B encoding RNA Polymerase III subunits cause an autosomal-recessive hypomyelinating leukoencephalopathy. *Am J Hum Genet*. 2011; 89(5):644-651.
- Sale MM, Smith SG, Mychaleckyj JC, et al. Variants of the transcription factor 7-like 2 (TCF7L2) gene are associated with type 2 diabetes in an African-American population enriched for nephropathy. *Diabetes*. 2007; 56(10):2638-2642.
- Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. *N Engl J Med*. 2007; 357(5):443-453.
- Saxena R, Gianniny L, Burt NP, et al. Common single nucleotide polymorphisms in TCF7L2 are reproducibly associated with type 2 diabetes and reduce the insulin response to glucose in nondiabetic individuals. *Diabetes*. 2006; 55(10):2890-2895.
- Steinthorsdottir V, Thorleifsson G, Reynisdottir I, et al. A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. *Nat Genet*. 2007; 39(6):770-775.
- Talmud PJ, Hingorani AD, Cooper JA, et al. Utility of genetic and non-genetic risk factors in prediction of type 2 diabetes: Whitehall II prospective cohort study. *BMJ*. 2010; 340:b4838.
- Teer JK, Bonnycastle LL, Chines PS, et al. Systematic comparison of three genomic enrichment methods for massively parallel DNA sequencing. *Genome Res*. 2010(a) 20(10):1420-1431.
- Teer JK, Mullikin JC. Exome sequencing: the sweet spot before whole genomes. *Hum Mol Genet*. 2010(b) 19(R2):R145-151.
- Thomas GS, Voros S, McPherson JA, et al. A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. *Circ Cardiovasc Genet*. 2013; 6(2):154-162.
- Thorleifsson G, Magnusson KP, Sulem P, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science*. 2007; 317(5843):1397-1400.
- Torkamani A, Topol EJ, Schork NJ. Pathway analysis of seven common diseases assessed by genome-wide association. *Genomics*. 2008; 92(5):265-272.
- Vaxillaire M, Veslot J, Dina C, et al; DESIR Study Group. Impact of common type 2 diabetes risk polymorphisms in the DESIR prospective study. *Diabetes*. 2008; 57(1):244-254.
- Vissers LE, Fano V, Martinelli D, et al. Whole-exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D-2-hydroxyglutaric aciduria (MC-HGA). *Am J Med Genet A*. 2011; 155A(11):2609-2616.

- Weedon MN. The importance of TCF7L2. Diabet Med. 2007; 24(10):1062-1066.
- Weinstein LB. Selected genetic disorders affecting Ashkenazi Jewish families. Fam Community Health. 2007; 30(1):50-62.
- Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007; 447(7145):661-678.
- Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014; 312(18):1870-1879.
- Yang X, Zabriskie NA, Hau VS, et al. Genetic association of LOXL1 gene variants and exfoliation glaucoma in a Utah cohort. Cell Cycle. 2008; 7(4):521-524.

Government Agency, Medical Society, and Other Authoritative Publications:

American College of Obstetricians and Gynecologists’ Committee on Genetics in collaboration with committee members Britton Rink, MD; Stephanie Romero, MD; Joseph R. Biggio Jr, MD; Devereux N. Saller Jr, MD; and Rose Giardine, MS. Carrier Screening for Genetic Conditions 2020

Texas Medicaid Provider Procedures Manual November 2020 [Accessed November 10, 2020](https://www.tmhp.com/sites/default/files/file-library/resources/provider-manuals/tmppm/archives/2020-11-TMPPM.pdf)
<https://www.tmhp.com/sites/default/files/file-library/resources/provider-manuals/tmppm/archives/2020-11-TMPPM.pdf>

American College of Medical Genetics and Genomics:
 Carrier screening in individuals of Ashkenazi Jewish descent Susan J. Gross, MD1 , Beth A. Pletcher, MD2 , and Kristin G. Monaghan, PhD3 , for the Professional Practice and Guidelines Committee 2008

Status	Date	Action
Approved	12/04/2020	Clinical & Administrative Advisory Committee Reviewed and Approved for Implementation

Original Document Creation Date: 10/21/2016	This Version Creation Date: 09/01/2020	Effective/Publication Date: 01/20/2021
---	--	--